Regulatory & Reimbursement
FDA Output March 2021
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and Diagnostic Emergency Use Authorizations in March 2021. Updated March 4.
Welcome to MyStrategist, the digital home for Market Pathways.
Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Regulatory & Reimbursement
What the Stark Law Changes Mean for Medtech
The recently-revised regulations to the Stark Physician Self-Referral Law have implications that extend beyond clinicians to medtech companies, particularly as the healthcare system increasingly evolves from volume to value-based programs. These expert healthcare attorneys explain why it is essential that medtech companies understand the full ramifications of this law’s current standards. By By Melissa Hudzik, Esq., and Jeff Weinstein, Esq., Wilson Sonsini Goodrich & Rosati.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Docs of the Month: IVDs a Strong Global Policymaking Focus in February
Sustained COVID-19 pressures continue to put IVDs in the spotlight—lab diagnostics were the most common topic of focus in February among global policy documents captured in Pathways’ Document Depot. A look at those docs and some other important releases from last month.